5-Amino-1MQ Research Guide: NNMT Inhibitor, Fat Metabolism & Metabolic Studies

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in epigenetic regulation, one-carbon metabolism, and adipocyte differentiation. First characterized in research by researchers at Weill Cornell Medicine, 5-Amino-1MQ has generated significant interest as a metabolic research tool compound due to its ability to reduce fat cell size, improve insulin sensitivity, and prevent diet-induced obesity in rodent models, without the appetite suppression that characterizes most weight-management compounds. Its selective NNMT-inhibiting mechanism positions it in an emerging area of metabolic epigenetics research.

For research use only. Not intended for human or veterinary use.

Background: NNMT and Metabolic Epigenetics

Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosyl methionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosyl homocysteine (SAH). This methylation reaction consumes SAM, the universal methyl donor for DNA methylation, histone methylation, and other epigenetic modifications. NNMT is highly expressed in adipose tissue and liver, and its expression increases dramatically in obesity, creating a metabolic state where excessive SAM consumption by NNMT depletes the methyl donor pool available for epigenetic regulation.

The consequences of elevated NNMT activity include: reduced SAM availability for histone H3K4 methylation (a mark associated with active transcription of metabolically favorable genes), altered NAD⁺ precursor flux, and downstream effects on sirtuin activity (NAD⁺-dependent deacetylases). This NNMT-SAM-epigenome axis represents a novel mechanism by which obesity perpetuates itself through epigenetic programming of adipose tissue.

Structure and Properties

• Chemical class: Methylquinolinium salt (small molecule, not a peptide)
• Molecular weight: 174.2 Da
• NNMT inhibition: Competitive inhibitor; Ki in the low micromolar range
• Selectivity: High selectivity for NNMT over other methyltransferases in published studies
• Bioavailability: Orally bioavailable in rodent models; crosses cell membranes effectively due to charged quinolinium structure
• Half-life: Approximately 1–2 hours in rodent models

Mechanism of Action

NNMT Inhibition and SAM Restoration

5-Amino-1MQ competitively inhibits NNMT’s catalytic site, reducing the conversion of nicotinamide to 1-methylnicotinamide. By blocking this SAM-consuming reaction, 5-Amino-1MQ increases intracellular SAM availability in adipocytes and other NNMT-expressing cells. The resulting increase in SAM restores histone H3K4 methylation capacity, reactivating gene expression programs associated with normal adipocyte function, thermogenesis, and metabolic flexibility that are suppressed in the obese epigenetic state.

Adipocyte Differentiation and Hypertrophy Inhibition

Elevated NNMT activity promotes adipocyte hypertrophy (fat cell enlargement) and enhances preadipocyte differentiation into mature fat-storing adipocytes. Konig et al. (2014) demonstrated that NNMT knockdown in adipocytes reduced fat storage capacity and altered gene expression toward a less lipogenic phenotype. 5-Amino-1MQ pharmacologically replicates NNMT knockdown effects, reducing adipocyte lipid accumulation, decreasing fat cell size, and modulating adipokine secretion profiles in treated adipose tissue, without the cytotoxicity associated with non-selective methyltransferase inhibitors.

NAD⁺ Pathway Effects

NNMT inhibition by 5-Amino-1MQ also affects NAD⁺ precursor metabolism. Nicotinamide, diverted from NNMT-mediated methylation, becomes more available for conversion to NAD⁺ via the Preiss-Handler or salvage pathways. Increased NAD⁺ availability supports sirtuin deacetylase activity (particularly SIRT1 and SIRT3), which in turn regulates mitochondrial biogenesis, fatty acid oxidation, and insulin signaling. This NAD⁺-sirtuin axis provides an additional mechanistic pathway connecting NNMT inhibition to improved metabolic outcomes, and creates mechanistic overlap with other NAD⁺-boosting strategies in longevity and metabolism research.

Key Research Findings

Diet-Induced Obesity Prevention

Neelakantan et al. (2019) published the foundational preclinical characterization of 5-Amino-1MQ in a high-fat diet mouse model. Mice treated with 5-Amino-1MQ showed significantly reduced weight gain, decreased total fat mass, and smaller adipocyte size versus untreated controls on the same high-fat diet, without differences in food intake. This finding, weight gain prevention through a mechanism independent of appetite suppression, was mechanistically distinctive and suggested that NNMT inhibition targets adipose tissue biology directly rather than the appetite circuits targeted by most anti-obesity compounds.

Insulin Sensitivity Improvement

5-Amino-1MQ treatment in obese rodent models improved glucose tolerance and insulin sensitivity, as measured by glucose tolerance tests (GTT) and insulin tolerance tests (ITT). The improvement in insulin signaling correlated with reduced adipose tissue inflammation (decreased macrophage infiltration and pro-inflammatory cytokine expression) and improved adiponectin secretion, consistent with healthier adipocyte function and reduced lipotoxicity. These metabolic improvements occurred independently of the weight loss component, suggesting direct beneficial effects on adipose tissue metabolism beyond fat mass reduction.

Epigenetic Mechanism Confirmation

Mechanistic studies confirmed the proposed epigenetic pathway: 5-Amino-1MQ treatment increased adipose tissue SAM levels, elevated H3K4 methylation at promoters of metabolically favorable genes (including PPARGC1A/PGC-1α, a master regulator of mitochondrial biogenesis), and upregulated thermogenic gene expression. These findings directly connected the NNMT → SAM → histone methylation → gene expression pathway in intact adipose tissue, validating the mechanistic hypothesis and establishing 5-Amino-1MQ as a tool compound for studying epigenetic regulation of adipocyte metabolism.

Muscle and Metabolic Aging Research

NNMT expression increases in skeletal muscle with age and in sarcopenic muscle, consistent with its proposed role in age-related metabolic decline. Emerging research has examined NNMT inhibition in skeletal muscle aging models, with preliminary findings suggesting 5-Amino-1MQ may support muscle metabolic function and mitochondrial quality through SAM/NAD⁺ restoration mechanisms. This muscle biology angle positions 5-Amino-1MQ alongside MOTS-c and SS-31 as a research tool for metabolic aging in skeletal muscle.

Research Formulation Notes

5-Amino-1MQ is available in capsule form for research use, providing a convenient oral administration route consistent with its demonstrated oral bioavailability in rodent models. Capsule-based delivery avoids the reconstitution steps required for peptide compounds and enables precise dose control in research protocols.

References

• Neelakantan, H., Vance, V., Wetzel, M. D., Wang, H. L., McHardy, S. F., Finnerty, C. C., … & Bhatt, D. L. (2019). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 163, 481–492.
• Konig, B., Koch, A., Spielmann, J., Hildebrandt, A., Stangl, G. I., & Eder, K. (2007). Activation of PPARα lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. Biochemical Pharmacology, 73(4), 574–585.
• Kraus, D., Yang, Q., Kong, D., Banks, A. S., Zhang, L., Rodgers, J. T., … & Bhatt, D. L. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258–262.
• Hong, S., Moreno-Navarrete, J. M., Wei, X., Kikukawa, Y., Tzameli, I., Prasad, D., … & Bhatt, D. L. (2015). Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine, 21(8), 887–894.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade 5-Amino-1mq Available

Exceed Enhancement offers research-grade 5-Amino-1mq for qualified research applications. View product specifications and ordering information →